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Numerous systems have been designed during the past three decades to improve
bioavailability of ophthalmic drug delivery, including: ocular prodrugs and
nanotechnology-based drug delivery system. The former can improve the efficacy of ocular
drug via enhancing corneal penetration of ocular drugs, prolonging their duration of action
and/or reducing the systemic side-effects, unfortunately, some characteristics of the pro-
drugs, such as poorly aqueous stability, poorly aqueous solubility and severe eye irritation
probably, limit their clinical practice and cannot be ignored. As we all know, nanotech-
nology for ocular drug delivery can carry poorly soluble drugs, protect the encapsulated
molecules from hydrolysis, control the rate of drug delivery and prolong the precorneal
retention of drugs. All of these merits may solve the problems in the utilization of ocular
prodrugs and increase the bioavailability of ocular drug delivery. By reviewing recent ad-
vances of prodrugs and nanostructures in ocular drug delivery, this paper focus specifically
on the promising prospects of nanocarriers overcoming the drawbacks of prodrugs for
ophthalmic drug delivery by precorneal routes.
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a s i a n j o u rn a l o f p h a rma c e u t i c a l s c i e n c e s 8 ( 2 0 1 3 ) 2 0 7e2 1 72081. Introduction nanostructures. Among them, Maria de la Fuente et al beganNumerous systems have been designed during the past three
decades to increase ophthalmic drug absorption. To improve
ocular penetration, one of the methods is to increase the
ocular contact time with the drug (vehicles and mechanical
obstruction of drainage). The common approaches to pro-
longing precorneal retention of ophthalmic drugs are viscous
solutions, suspensions, ointments, gels, thermosetting gels,
polymeric inserts, micro- and nanocarriers ([le3] and refer-
ences cited therein). Furthermore, prodrug, soft-drug and the
chemical delivery system (CDS) are other chemical ap-
proaches for improving ophthalmic drug delivery by
improving drug penetration across the cornea.
It has been estimated that only 1e2% (or less) of an instilled
dose of ocular drugs penetrates the inner eye, with the
remaining dose reaching the systemic circulation. This poor
bioavailability is mainly because of the lipophilicity of the
corneal epithelium, which restricts corneal drug penetration,
especially, of hydrophilic drugs, and of precorneal processes
that eliminate the drugs rapidly from the absorption site.
Transforming potent drugs into prodrugs to increase lip-
ophilicity is our aim so that absorption through the corneal
lipophilic epithelium is improved. Prodrugs were introduced
into ophthalmology about 35 years ago when ophthalmic ab-
sorption of epinephrine was improved by its prodrug, dipi-
vefrine. This prodrug has been substituted for epinephrine in
therapy for the elevated intraocular pressure (IOP) associated
with glaucoma. A promising ocular prodrug should be stable
and soluble in aqueous solutions to achieve formulation,
sufficiently lipophilic in order to penetrate across the cornea,
non-irritative, and capable of releasing the parent drug within
the eye at a rate that achieves the therapeutic goals [4]. After
dipivefrine, various prodrugs have been designed to improve
the efficacy of ocular drugs, to prolong their duration of action
and/or to reduce the systemic side-effects associated with
many ocular drugs. Prodrugs have been tested experimentally
and clinically; however, problems of stability and solubility as
well as local irritation have still produced consequences that
have limited the efficacy and clinical acceptability of
ophthalmic applied prodrugs.
Another major problem in ocular therapeutics is how to
keep and maintain an effective drug concentration at the site
of action for an appropriate period of time, in order to obtain
the desired pharmacological responses [5]. Ophthalmic drug
delivery, probably more than any other route of administra-
tion, may benefit from the characteristics of nanotechnology-
based drug delivery systems [6]. Interesting opportunities for
topical ocular drug delivery are provided by the use of nano-
carriers, mainly because of their capacity to protect the
encapsulated molecule and facilitate its transport to different
areas of the eye [7]. Additionally, nanostructuresmay offer the
possibility of controlling drug delivery, thus providing effec-
tive approaches for therapeutics in some chronic ocular dis-
eases [8]. Other alternatives for topical drug delivery involve
the use of liposomes, microemulsions and microparticles,
among others.
Over the last two decades, much research has been
devoted to the rational development of ocular drug deliverytheir research into ocular drug delivery with the development
of hydrophobic nanostructures consisting of poly-
alkylcyanoacrylate [9] and polyesters, especially poly-ε-cap-
rolactone [10]. This research led to the conclusion that these
nanostructuresmake contact with the corneal epithelium and
also suffer a certain aggregation upon affinity toward the
mucosal surface. Moreover, further research shows that it is
possible to give the nanostructures with a hydrophilic coating
to improve their stability and their interaction with the mu-
cosa. To achieve this goal, the researchers selected hydro-
philic materials, i.e., polyethyleneglycol (PEG) and chitosan
(CS) [11]. PEG was selected because of its well-known protein-
rejecting properties (shielding effect). The choice of CS, a
cationic polysaccharide, was mainly on account of its
mucoadhesive and penetration-enhancing properties, as well
as its ideal biocompatibility with ocular structures [12]. The
very promising results obtainedwith CS-coated systems led to
the further development of nanostructures made of solely
hydrophilic polysaccharides such as CS alone or in combina-
tion with cyclodextrins and hyaluronic acid [13].
Nevertheless, the methodsmentioned above have resulted
in only moderate success; improving precorneal drug reten-
tion alone is inadequate in bringing about marked improve-
ment in ocular drug bioavailability. Moreover, improving the
ability of the drug to penetrate the ocular membranes must
also be considered [14]; at the same time, drawbacks resulting
from the increasing lipophilicity of potent ocular drugs should
not be ignored. This paper aims to review the usefulness of
prodrugs and nanostructures in ocular drug delivery, which
has been discussed comprehensively in earlier reviews. A
brief summary concerning themain characteristics of prodrug
absorption after ophthalmic delivery is described below to
raise the possibility that prodrugs could be delivered via
nanostructures, e.g., a nanostructured lipid carrier (NLC)
coated with chitosan. By this method, we may succeed in
prolonging the retention time of ocular prodrugs, improving
the stability and solubility of prodrugs in aqueous solutions,
reducing irritation, and releasing prodrugs at a controlled rate.2. Barriers in ophthalmic therapeutics
The first choice of delivery in ophthalmic therapy is topical
instillation of an active compound. However, the innate pro-
tective characteristics of the eye against the entry of foreign
compounds result in the generally low bioavailability of an
instilled drug.
The eyeball consists of two anatomical regions: the ante-
rior segment and the posterior segment. In the former, the
cornea and conjunctiva are the prominent structures, and in
the latter, the retina plays a significant role.
Themain route bywhichmost ocular drugs enter the eye is
generally considered to be through the cornea, which is
anatomically composed of five to seven layers. They are the
epithelium, Bowman’s membrane, stroma, Descemet’s
membrane, and the endothelium, but only the epithelium,
stroma, and endothelium can be obstacles to drug absorption.
Usually, the lipophilic corneal epithelium, six or seven cell
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the eye. There are intercellular tight junctions (zonula occlu-
dens) completely surrounding most of the superficial corneal
epithelium cells. These tight junction structures serve as a
kind of selective obstacle for small molecules, and macro-
molecule absorption via the paracellular pathway is
completely prevented. Another barrier to drug absorption is
the stroma, which is different from the epithelium. The
stroma is a highly hydrophilic tissue, consisting mostly of
water; owing to its property of relative openness, drugs of a
molecular size up to 500,000 Da can diffuse in normal stroma
[15]. Nevertheless, when it comes to most lipophilic drugs, the
corneal stroma represents a rate-limiting barrier to access the
inner eye. This is because lipophilic compounds will partition
from the lipophilic epithelium to the hydrophilic stroma; in
fact, the stroma may act as a reservoir from which the drug
will be slowly delivered to the aqueous humor. Finally, the
moderately lipophilic corneal endothelium, which consists of
a very thin layer of cells, does not offer significant resistance
to drug absorption.
With respect to the conjunctiva, despite it being a hundred
times more permeable than the cornea for large hydrophilic
compounds [16] and playing a critical role in achieving the
influx and efflux transport of drugs in the conjunctiva, it
should also be noted that the presence of lymphatic and blood
vessels can lead to significant systemic absorption [17], which
may produce some unexpected systemic side-effects.
A mucus layer, called the lachrymal film, which covers
both corneal and conjunctival structures and is part of the tear
film, is secreted by the goblet cells of the conjunctiva. It plays a
significant function in hydrating, cleansing, lubricating, and
serving as a defense against pathogens, and is also an obstacle
to any drug penetration [18]. Moreover, the lachrymal film is a
dynamic fluid that undergoes continuous renewal. Conse-
quently, it decreases the precorneal retention time of drugs on
the surface of the eye.
In addition,metabolic enzymes such as esterase, aldehyde,
and keton reductases contained in ocular tissues [19] may
degrade and reduce the efficacy of the drugs. On account of
these anatomical and physiological constraints [17], much of
the drug delivered via topical instillation is removed by
different mechanisms, resulting in very low ophthalmic
bioavailability, and sometimes even causing relatively serious
systemic side-effects.3. Routes of ocular drug absorption across
the cornea
There are two obvious pathways by which ocular drugs can
diffuse across the corneal epithelium into the inner eye: one is
the paracellular pathway, and the other is the transcellular
pathway. Hydrophilic drugs prefer the paracellular pathway,
which involves passive or altered diffusion across intercel-
lular spaces [20], and the stratified corneal epithelial cell layer
can be characterized as a “tight” ion-transporting tissue [21];
this is the reason why the paracellular pathway exhibits high
resistance to the paracellular diffusion of solutes. The limiting
size of the paracellular pathway appears to be in the order of
60 A` or less, the molecular size of glycerol [22]. Nevertheless,the total surface area of the cornea exposed to the tear that is
attributable to the paracellular pathway is very small; most of
the ocular drugs would probably opt for the transcellular
pathway through the cornea. Physicochemical properties of
the drugs that influence drug penetration via the transcellular
pathway include: (1) the lipophilicity of the drug, reflected by
its n-octanol/buffer partition coefficient; (2) its pKa, which
determines the amount of drug absorbed into eyes as its
preferentially absorbed form at a given pH; and (3) molecular
size. Of all these properties, lipophilicity is the best under-
stood and studied. Parabolic [23] and sigmoidal [24] relation-
ships have been found to describe the influence of drug
lipophilicity on corneal drug penetration. Such correlations
have been reported for beta blockers [25], steroids, alkyl p-
amino-benzoates [26], and aniline derivatives [27]. It is re-
ported that the optimum partition coefficient for corneal drug
penetration is in the range of 100e1000.4. Prodrugs/double-prodrugs
Prodrugs are pharmacologically inactive derivatives of drug
molecules that require a chemical or enzymatic trans-
formation in order to release the active drug within the body
[28]. In most cases, prodrugs are simply chemical derivatives
that are one or two chemical or enzymatic steps away from
the parent drugs. Enzymatic transformation of prodrugs in
ophthalmic tissue is often used to release the parent drug.
Many ocular drugs contain hydroxyl or carboxyl groups that
can be esterified to lipophilic ester-prodrugs. In the cornea,
the esterase activity in the epithelium is about 2.5 times
higher than that in the stroma- endothelium [29]. Moreover,
the absence of acetylcholinesterase (AChE) and butyr-
ylcholinesterase (BuChE) in tears [30], which are contained in
the ocular tissue of rabbits [31], ensures the absorption of
intact ester-prodrug into the corneal epithelium. Double-
prodrugs (pro-prodrugs) [32] are derived in such a manner
that enzymatic hydrolysis is required before spontaneous
(chemical) release of the active drugs. To some extent, the
increase in double-prodrugs could solve the problems of
instability in ester-prodrugs.
In general, it is not well known whether prodrugs (e.g.,
dipivefrin) are substrates for BuChE or for AChE. An optimal
ester-prodrug, however, should be hydrolyzed by several es-
terases to minimize the effect of individual esterase levels on
the enzymatic transformation of ophthalmic prodrugs [33].4.1. Merits of prodrugs
Prodrugs were initially introduced to ophthalmology about
three decades ago with the testing of dipivalyl epinephrine as
a method for improving the corneal penetration of epineph-
rine. Thus far, of all the methods (use of penetration en-
hancers, ion pair formation, and prodrug methods) for
enhancing corneal drug absorption, the prodrug approach is
the only approach that has been commercially realized. Since
then, this approach has been extended to several other
ophthalmic drugs with the objective of achieving one of the
following outcomes via enhanced corneal penetration.
a s i a n j o u rn a l o f p h a rma c e u t i c a l s c i e n c e s 8 ( 2 0 1 3 ) 2 0 7e2 1 72104.1.1. Enhanced ocular potency
In the case of the epinephrine prodrug, dipivefrine, a dipivalyl
ester-prodrug of epinephrine, which releases epinephrine
after corneal absorption, has currently taken the place of
epinephrine in therapy for glaucoma [30,34,35]. It has better
ability to penetrate across the cornea, being 17 times higher
than that of epinephrine [36] because dipivefrine is 600 times
more lipophilic (at pH 7.2) than epinephrine. As a result, a
smaller topical dose of dipivefrine achieved a similar thera-
peutic effect in the eye [37].
Another case is phenylephrine. Phenylephrine is an alpha-
adrenergic agent used clinically for pupil dilation in eye ex-
aminations or in ocular surgery. Its ophthalmic bioavailability
is low because of its hydrophilic nature (log Papp ¼ 1.89 [38]
and reference cited therein), and concentrated phenyleph-
rine eyedrops (up to 10%) are essential to produce mydriasis.
Its prodrug, phenylephrine oxazolidine, is a lipophilic (log
Papp ¼ 1.38) compound. Compared with 10% phenylephrine
eyedrops, 10% oxazolidine prodrug eyedrops raised the
amount of phenylephrine in the aqueous humor by 6e8 times
and improved mydriatic activity fourfold in rabbits [38]. In
clinical trials with healthy subjects, 1% phenylephrine oxa-
zolidine produced better papillary dilation than 10% phenyl-
ephrine [39].
With respect to the case of beta-adrenergic antagonists,
the timolol prodrug is a typical example. Timolol is a basewith
a pKa value of 9.2 [25]. At physiological pH, 98% of timolol is
protonated and shows a low lipophilicity [40]. Its hydrophilic
nature reduces corneal penetration, and less than 5% of theFig. 1 e Chemical structures and partition coeffiinstilled dose is absorbed into the deep eye structure [41]. To
solve this problem, various alkyl, cycloalkyl, aryl esters, and a
carbamate ester have been synthesized by esterifying reaction
(Fig. 1). These prodrugs were studied, and proved to be more
lipophilic than timolol [23,40]. Compared with the same con-
centration of timolol solution, O-butyryl timolol improved the
corneal penetration of timolol four to six-folds because of its
increased lipophilicity [42,43].
To sum up, the lipophilicity of some ocular drugs is
improved by transforming them into prodrugs, and the
amount of these drugs absorbed into the eye also increased as
a result of the correlation between drug lipophilicity and drug
corneal permeability. Despite the fact that it is more compli-
cated to evaluate the optimal Papp value for corneal perme-
ability because their corneal permeability depends on both the
lipophilicity of prodrug/parent drug and the reversible rate of
prodrug to the active drug, the potency of ophthalmic drugs is
improved by to some extent. The same situation can also be
found in the prodrugs of some carbonic anhydrase inhibitors
[44] steroids [45], and antiviral compounds [46].
4.1.2. A lower incidence of systemic side-effects through
reduction in the instilled dose
The usefulness of prodrugs in lowering systemic absorption of
topically applied drugs is exemplified by the prodrugs of
timolol [47], phenylephrine [48], and terbutaline [49].
Among the prodrugs of timolol mentioned above,
compared with an equivalent timolol solution, O-butyryl
timolol increased the corneal absorption of timolol four to six-cient of various prodrug esters of timolol.
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the nasal mucosa and conjunctiva of the eye [42]. The results
can be explained by a study indicating that corneal drug ab-
sorption is more sensitive than conjunctival absorption to
changes in drug lipophilicity [24]. The increasing timolol
concentration in the aqueous humor and the decreasing sys-
temic absorption of timolol improved the ratio of aqueous
humor concentration to plasma concentration, and thus the
objective of reduced side-effects could be achieved.
When it comes to phenylephrine oxazolidine, the prodrug
of phenylephrine, the same results can also be obtained.
Because of the hydrophilic nature of phenylephrine, a high
concentration of phenylephrine eyedrops (up to 10%) isFig. 2 e Chemical structures and characteristics of varequired to produce mydriasis. Owing to systemic absorption,
adverse systemic side-effects such as hypertension, ventric-
ular arrhythmia, and possible myocardial infarction may be
caused by a large topical dose. On the contrary, in monkeys,
1% phenylephrine oxazolidine was shown to increase mydri-
atic response and decrease plasma levels of phenylephrine
compared with 10% phenylephrine [38], and only minor sys-
temic side-effects were obtained.
Reducing the systemic absorption of topically applied
drugs is achieved by either reducing the instilled dose in
proportion to the degree of enhancement in corneal drug
penetration [42,43] or increasing the lipophilicity of the pro-
drugs, thereby impeding their absorption into the systemicrious monoesters and diesters of pilocarpic acid.
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tion [50].4.2. The drawbacks of ocular prodrugs
Although prodrugs have great promise in improving ocular
drug delivery, their clinical usefulness may be limited by their
disadvantages.
4.2.1. Poor aqueous stability
The timolol prodrug, prodrug of beta-adrenergic antagonists,
is a promising example, penetrating the cornea substantially
better than timolol [23], but the rate of ester hydrolysis of
alkyl, cycloalkyl, and aryl ester-prodrugs was about equal in
plasma and phosphate buffer, which makes it difficult to
design a prodrug that is stable in vitro but will convert quickly
to an active drug in vivo. Consequently, the poor aqueous
stability of the prodrugs hinders their clinical usefulness
although they have good biopharmaceutical characteristics.
Another prodrug of beta-adrenergic antagonists, oxprenolol
prodrugs, which have been developed for ocular use [51], may
be limited by their poor aqueous stability (t90% at 10C ¼ 1e230
days).
The same problems occurred in the case of pilocarpic acid
monoesters, which were developed as prodrugs of pilocarpine
(Fig. 2) by Bundgaard et al [52]. These prodrugs were more
lipophilic than pilocarpine and improved the ophthalmic
bioavailability (miosis was used as bioassay) of the parent
drug. However, their practical use was limited by the poor
aqueous stability of the monoesters (t1/2 at 37 C in aqueous
solution (pH 7.4) ¼ 0.5e18 h). Although monoesters are more
stable in acidic solutions, the preparation of ready-to-use
eyedrops with an acceptable shelf-life was not possible. Al-
buterol (salbutamol) is a beta-adrenergic agonist used for
decreasing intraocular pressure (IOP) but some side-effects
were found. In order to increase the therapeutic index (i.e.,
the aqueous humor to plasma absorption ratio) of topical
applied albuterol and decrease its side-effects, albuterol tri-
mesters (Fig. 3) were prepared. Although the triester prodrugs
of albuterol produced a better hypotensive effect than albu-
terol in hypertensive rabbits, its further use in preparing sta-
ble ready-to-use eyedrops was limited because it degraded in
aqueous solutions.Fig. 3 e Chemical structures of several albuterol prodrug
trimesters.4.2.2. Poor aqueous solubility
Although some lipophilic prodrugs present a promising ocular
absorption, their highly lipophilic nature leads them to be
difficult to dissolve in an aqueous medium, and raises a
challenge in drug delivery in the form of eyedrops, in which
formmore than 90% ofmarketed ophthalmic formulations are
developed. Such situations are exemplified by O-palmitoyl
timolol [54] and pilocarpic acid diesters [53].
In the case of O-palmitoyl timolol, the prodrugs were
administered in rabbits as a dispersion, because of low
aqueous solubility, which may produce poor patient compli-
ance and hinder their further use clinically. With respect to
pilocarpic acid diesters, although such prodrugs were syn-
thesized by esterifying the alcoholic hydroxyl group of pilo-
carpic acid monoester (Fig. 2), which overcame the aqueous
stability problem of pilocarpic acid monoesters using the
double-prodrug concept, its low aqueous solubility at pH
values higher than 4.5 [55] could be a barrier, hindering
preparations and limiting its practical use.
4.2.3. Eye irritation
In the study of the ocular delivery of pilocarpic acid diesters
using rabbit miosis as a bioassay, although the pilocarpine
prodrugs (equivalent to 0.25% or 0.5% pilocarpine solution)
showed extended duration of miosis from 3 h (pilocarpine) to
4e5 h and decreased the peak miotic response [56], these
pilocarpine prodrugs also caused serious eye irritation
immediately after eyedrop administration, and this irritation
increased with rising lipophilicity of the prodrugs. Suhonen
et al thought this irritation was caused by rapid absorption of
the lipophilic prodrug into the lipophilic corneal epithelium
and/or precipitation of prodrug molecules in the precorneal
area and/or specific toxicity of the bispilocarpic acid diester
[57]. Moreover, Paula Saarinen-Savolainen et al. concluded
that the amphiphilic properties shown by lipophilic pilocar-
pine prodrugs may contribute to eye irritation, and the
harmful effects of pilocarpine prodrugs on the cell mem-
branes of ocular surfaces may limit their usefulness. Possible
amphiphilicity of lipophilic prodrugs may be an obstacle to
use of the prodrug technique in ocular delivery [59].5. Nanotechnology in ophthalmic drug
delivery
5.1. Nanostructures vs. conventional dosage forms
Nanotechnology has led to an important revolution in
different therapeutic areas. Owing to numerous challenges
happened in the treatment of ocular disorders, ophthalmic
drug delivery, probably more than any other route of admin-
istration, may benefit from the use of nanotechnology-based
drug delivery systems [60].
Most ocular disorders are treated by topical instillation in
the form of solutions, suspensions, and ointment. Although
the external eye structures are accessible, the tightness of
corneal epithelium obstruction, as well as rapid precorneal
drug elimination and systemic absorption from the conjunc-
tiva, restrain ophthalmic absorption of topical applied drugs
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conventional forms and the anatomy, physiology, and
biochemistry of the eye, nanocarriers may provide promising
opportunities for topical ocular drug delivery, not only to
facilitate drug efficacy, but also to reduce side-effects [62]. The
exemplified by nanosuspensions, solid lipid nanoparticles,
and liposomes, has led to the solving of various solubility-
related problems of poorly soluble drugs [63]. Nanospheres
and liposomes, can provide protection for the drug encapsu-
lated in them, and thus prolong exposure to the drug by
controlled release. To develop a promising and suitable ocular
drug delivery system, various criteria need to be considered,
and some formulation parameters are (given in Table 1) [74].
5.2. Nanostructures vs. prodrugs
As the advantage of prodrugs, high corneal permeability
resulting from their increased lipophilicities, may improve the
bioavailability of the parent drug and lower absorption into
the systemic circulation, accordingly, the systemic side-
effects are decreased. Nevertheless, this promising delivery
form is not devoid of pitfalls, such as eye irritation, poor
aqueous stability and solubility, which were described above
and represent limitations to their clinical practice.
With the development of nanotechnology-based drug de-
livery systems, the drawbacks of prodrugs may be overcome
by the use of nanocarriers.
5.2.1. Problem of poor aqueous solubility may be approached
via nanocarriers
Nanosuspensions are composed of pure, poorly water-soluble
drugs, suspended in a suitable dispersion medium. In general,
this form of nanocarrier is prepared from inert polymeric
resins and produces no irritation in the cornea, iris, or con-
junctiva. Nanosuspensions have several merits in improving
the water-solubility of insoluble drugs, e.g., increased satu-
ration solubility and consequently an increased dissolution
rate. In the formulation of the new phospholipase A2 through
ophthalmic drug delivery [64], PX-18(2-N,N-Bis(oleoylox-
yethyl)amino-1-ethanesulfonic acid), which is a new highlyTable 1 e Criteria for the selection of optimal formulation
parameters when developing an ophthalmic drug
delivery system.
Factors Preference
Drug Preferentially lipophilic. Non-ionizable lipophilic
compounds will concentrate in the corneal
epithelium, whereas ionizable lipophilic ones
will partition into the aqueous humor
Vector type Depends on encapsulated molecule. Should allow
a high loading dose to reduce the amount of
instilled drug
Carrier size Lowest possible to facilitate corneal uptake and
passage
Osmotic
pressure
Isotonic with physiological fluids to avoid irritation
and lacrimation
pH Close to physiological pH to avoid irritation and
lacrimation. If buffering is necessary, the lowest
possible buffer concentration should be used
(<0.1 M)potent PLA2 inhibitor (Fig. 4) [65,66] that is poorly soluble in
aqueous media [67], it was proved that this drug could be
prepared as a nanosuspensions with content of 1% (w/w), 5%
(w/w), and 10% (w/w). In the case of non-steroidal anti-in-
flammatory drugs (NSAIDs), the same problem of poor water-
solubility causes difficulty in preparing eyedrops and lower
bioavailability. Kocbek et al formulated ibuprofen, an NSAID,
as a nanosuspension, and the results indicated that the
nanosuspension is highly successful in enhancing the disso-
lution rate. Similarly, different hydrophobic drugs have
already been delivered in the same way, for instance nap-
roxen [68], clofazimine [69], bupravaquone [70], nimesulid [71],
and mitotane [72]. In all this previous research, the drugs
chosen as model drugs are lipophilic which is similar to the
prodrugs mentioned above. For the characteristic of the hy-
drophilicity of NSAIDs, author determined the apparent
partition coefficient (Papp) of several NSAIDs in octanol/buffer
(pH 7.4) via shake-flaskmethod. The results are (given in Table
2), and it is apparent that the Papp is in the range of 100e1000,
which is the same as the range of optimum Papp values re-
ported in previous research. According to this evidence, the
authors inferred that the same solution used in improving the
solubility of lipophilic drugs such as NSAIDs could also be
applied to prodrugs for the preparation of eyedrops, to
enhance the compliance of patients and decrease some un-
necessary side-effects.
Cyclodextrins (CDs) are a group of cyclic oligosaccharides
capable of forming inclusion complexes withmany drugs [73].
In ophthalmic preparations, co-administration of CDs has
been reported to increase the water-solubility of drugs such as
dexamethasone, cyclosporine, acetazolamide, and so on [74].
Also, some other nanotechnology-based drug delivery
systems such as solid lipid nanoparticles and liposomes could
lead to the solving of solubility-related problems in poorly
soluble drugs [74], such as the prodrugs.
5.2.2. Problem of poor aqueous stability may be solved by
nanotechnology-based drug delivery systems
As mentioned above, some prodrugs have great potential in
improving the bioavailability of parent drugs, but their clinical
application is limited because of their poor aqueous stability,
as exemplified by the timolol prodrug and pilocarpic acid
monoesters (pilocarpic prodrugs)N
SO3H
O
OO
O
C42H79O7NS
Fig. 4 e Chemical structure and molecular formula of
PX-18.
Table 2e Partition coefficient of drugs betweenwater and
n-octanol (n[ 5).
Drugs C0 (i.g. mL
1) Cw (i.g. mL
1) log Poct/w
Loxoprofen 327.89  2.37 19.38  0.90 1.2018
Ketoprofen 204.76  8.58 9.20  0.53 1.3274
Naproxen 34.21  0.79 1.48  0.04 1.3433
Flurbiprofen 20.92  0.55 0.98  0.07 1.4082
Ibuprofen 61.06  2.46 2.18  0.11 1.4314
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ber of advantages for the delivery of aqueous unstable drugs
to the ocular surface. A liposome is a vesicle containing a lipid
bilayer, consisting of unimers that usually have a hydrophilic
head and a hydrophobic tail and are oriented so that the hy-
drophobic headgroups are inside the bilayer. Lipophilic drugs
can be encapsulated in the hydrophobic bilayer within the
liposome to improve stability, compared with free drugs. The
entrapment of lipophilic drugs or prodrugs has been shown to
be useful in providing protection against hydrolytic decom-
position of the drugs. The lipophilic prodrugs are located in
the phospholipid bilayers and represent resistance to hydro-
lysis. An example is campothecin, an antitumor drug, which is
hydrophobic but contains a lactone ring that rapidly hydro-
lyzes to an inactive carboxylate form. This antitumor drug
shows high binding affinity (97%) in liposomes, and its lactone
functionality partitions into the bilayer [75]. On account of this
protective effect, no ring opening occurred for 72 h in lipo-
somes that were composed of phospholipids with low tran-
sition temperatures, i.e. DMPC (T z 24 C), which is in its
unstable liquid crystal phase at 37 C. It is definitely a prom-
ising improvement compared with the t1/2 of free campto-
thecin at just 16.6 min [76]. In addition, the activity of several
lipophilic prodrugs that are incorporated into liposomes has
proved to be effective in improving the stability of liposomes
and preventing leaching of the drug. A related case is exem-
plified by cytosine arabinoside [77].
Niosomes may be another solution to the problem of poor
aqueous stability of ocular prodrugs. Niosomes are non-ionic
surfactant vesicles and, like liposomes, they are bilayered
structures, that can entrap lipophilic drugs in the lipid bilayer.
The mechanism by which niosomes protect lipophilic pro-
drugs from hydrolysis is similar to that of liposomes
mentioned above. Moreover, compared with liposomes, nio-
somes have the merits of chemical stability and, unlike
phospholipids, the addressing of surfactants does not require
special precautions and conditions; they are biodegradable,
biocompatible, and non-immunogenic [78].
With respect to CDs, it is reported that cyclodextrins can
increase the aqueous stability of ophthalmic drugs [79,80]. In
the case of the timolol prodrug, Bundgaard et al aimed to in-
crease the aqueous stability of timolol prodrugs via b-CD co-
administration [40]. However, the studied concentration of b-
CDswas very low (0.5% due to the poor aqueous solubility of b-
CD), andno encouraging improvement in the aqueous stability
of theprodrugswasobtained.Nonetheless, itmightbepossible
to improve the stability of timolol prodrugs with higher con-
centrations of water-soluble b-CD derivatives such as
hydroxypropyl b-CDs [81] and sulfobutyl ether b-CDs [82]. Theapplication of cyclodextrins in improving the aqueous stability
of ocular prodrugs may be studied in further research.
5.2.3. Possible application of nanocarriers in mitigating the
irritation of ocular prodrugs
In the study of pilocarpine prodrugs, it was found that these
prodrugs cause significant eye irritation, and with increasing
lipophilicity of the prodrug, eye irritation increases after
eyedrop administration. This irritation was thought be due to
rapid absorption of the lipophilic prodrug into the cornea and/
or precipitation of prodrug molecules in the precorneal area
[57,58].
CDs are very effective at decreasing drug irritation, because
theymask the irritative effects of the drugs by the formulation
of inclusion complexes. To return the case of severe irritation
from pilocarpine prodrugs, it has been found that pilocarpine
prodrug/sulfobutylbutylether b-CD (SBE-7-b-CD) complexes
act as a depot that limits free prodrug concentration at the
precorneal area to a non-irritating level [83].
The use of contact lenses loaded with nanoparticles can be
an effective alternative to topical application of ophthalmic
drugs in the form of eyedrops. One problem is that contact
lenses soaked in drug solution cannot be used for long-term
delivery. To increase the duration of drug delivery from con-
tact lenses, the drug can first be entrapped in vesicles, such as
liposomes, or nanoparticles; then such nanoparticles can be
dispersed throughout the contact lens material. This solution
provides additional resistance to drug release: first, the drug
must diffuse through the nanoparticle and then penetrate the
particle surface to get to the hydrogel matrix. Previous studies
have indicated that the drug residence time was markedly
prolonged, and there were two separate time stages for drug
release: an initial burst (releasing 50% of the drug) in the first
few hours and then slower release over a few days [84,85]. The
author thought that this technology of nanoparticle-loaded
contact lenses could be introduced to solve the problem of
irritation fromocular prodrugs due to the possiblemechanism
by which the lipophilic prodrug is rapidly absorbed into the
lipophilic corneal epithelium. By means of changing or
modifying the matrix materials of contact lenses and pre-
paring the nanocarriers which may have some characteristics
to control the rate of drug release, the lipophilic prodrugs
could be absorbed at a rational rate and the irritation from
prodrugs could be decreased significantly.6. Further perspective
Generally, when it comes to ophthalmic drug delivery, because
of the critical and pharmacokinetically specific environment
that exists in the eye, two methods are used to improve the
poor bioavailability of topically applied ocular drugs: the first is
prolonging precorneal retention time, and the other is
improving drug penetration across the cornea. With respect to
the first solution, traditionally, common approaches, such as
viscous solutions, suspensions, ointments, gels and so on, can
prolong corneal retention of ocular drugs to some extent, but
some side-effects such as irritation and inconvenience such as
increasing instillation times can occur. Their application is
limited because of poor patient compliance. Therefore, only
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inadequate in bringing about a significant improvement in
bioavailability. Another method to improve the ability of the
drug to penetrate the ocular membranes must also be
considered. Various lipophilic ocular prodrugs have been
synthesized which represents a promising approach to
increasing the efficiency of corneal absorption of ocular drugs.
Nonetheless, these prodrugs present numerous problems such
as poor aqueous solubility and stability, severe irritation, and
so on, which to some extent limits the clinical application of
ocular prodrugs. With the development of nanotechnology,
nanotechnology-based drug delivery systems provide more
opportunities for ocular drug delivery.
The author believes that a method of prolonging pre-
corneal retention of ocular drugs and a method of enhancing
the ability to penetrate the corneal membrane should be
considered together, which means, lipophilic prodrugs could
be incorporated into or with nanotechnology-based drug de-
livery systems for ophthalmic drug delivery. On the one hand,
the lipophilic nature of prodrugs is suitable for formulation as
nanocarriers, such as liposomes, nanosuspension, nano-
particles, and niosomes. In some casesmentioned above, high
lipophilicity could also improve the stability of nanocarriers
(e.g., liposomes) and decrease the leakage of drug from
nanocarriers. To some extent, some problems with prodrugs
may be approached by incorporating them into nanocarriers,
such as increasing aqueous solubility and stability and
lowering irritation and other side-effects. The approach of
using prodrugs incorporated into nanocarriers could remove
limitations to the application of some promising prodrugs in
clinical practice. The objective of improving corneal penetra-
tion could be significantly achieved. On the other hand, based
on the properties of nanocarriers (e.g., nanoparticles and li-
posomes), which vary substantially in composition, size, and
surface charge, nanotechnology-based drug delivery systems
could prolong precorneal retention by contacting intimately
with the corneal membrane. Moreover, nanoparticles made
up of other natural polymers, such as chitosan, are also
effective in intraocular penetration of drugs, because of their
ability to contact intimately with the corneal and open the
tight conjunctions in the cornea. In addition, nanoparticles
coated with different polymers show the characteristic of
adhesion to mucus [11]. This approach could also increase the
precorneal retention of drugs. Nanotechnology-based drug
delivery systems for ocular drug delivery could prolong pre-
corneal retention of ophthalmic drugs, and there are no
drawbacks in traditional methods.
But in the development process of nanotechnology-based
drug delivery systems, the problems still exist for further
consideration. The security of the excipients (biocompati-
bility, biodegradability and toxicity) is the first issue to be
considered. In addition, optimal drug loading and controlling
the drug release rate are also important issues.
In summary, incorporating the prodrugs into
nanotechnology-based carriers combines the method of
improving drug penetration across the cornea with the
method of prolonging precorneal retention of drugs and may
provide more effective opportunities to overcome the barriers
in ocular therapeutics and improve the bioavailability of
ophthalmic drug delivery.Acknowledgments
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